After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

“It’s a matter of how, for whom, and at what price?” Read more from Jonathan. Peak U.S. sales of Humira, made by pharmaceutical giant AbbVie, were $18.6 billion in 2022. Then, in ...

This step up from the standard Stylo 3 has a better screen, more memory, and NFC. Other features of this large Android phone are similar, including a large 5.7-inch screen with stylus, and a ...

This variant of the Stylo 2 has a fingerprint reader and MediaTek processor. This large Android phone has a huge 5.7-inch screen and includes a stylus. Other key features include a 13-megapixel ...